BACKGROUND: Heart-type fatty acid binding protein (hFABP) functions as a myocardial fatty acid transporter and is released into the circulation early after myocardial injury. We hypothesized that hFABP is superior to conventional cardiac biomarkers for predicting early perioperative myocardial injury after coronary artery bypass graft (CABG) surgery. METHODS: A prospective cohort study of 1298 patients undergoing primary CABG with cardiopulmonary bypass (CPB) was performed at 2 institutions. Four plasma myocardial injury biomarkers (hFABP; cardiac troponin I [cTnI]; creatine kinase, MB [CK-MB] fraction; and myoglobin) were measured at 7 perioperative time points. The association among perioperative cardiac biomarkers and ventricular dysfunction, hospital length of stay (HLOS), and up to 5-year postoperative mortality (median 3.3 years) was assessed using Cox proportional hazard models. We defined in-hospital ventricular dysfunction as a new requirement for 2 or more inotropes, or new placement of an intraaortic balloon pump, or ventricular assist device either during the intraoperative period after the patient separated from CPB or postoperatively in the intensive care unit. RESULTS: The positive and negative predictive values of mortality for hFABP are 13% (95% confidence interval [CI], 9%-19%) and 95% (95% CI, 94%-96%), respectively, which is higher than for cTnI and CK-MB. After adjusting for clinical predictors, both postoperative day (POD) 1 and peak hFABP levels were independent predictors of ventricular dysfunction (P < 0.0001), HLOS (P < 0.05), and 5-year mortality (P < 0.0001) after CABG surgery. Furthermore, POD1 and peak hFABP levels were significantly superior to other evaluated biomarkers for predicting mortality. In a repeated-measures analysis, hFABP outperformed all other models of fit for HLOS. Patients with POD2 hFABP levels higher than post-CPB hFABP levels had an increased mortality compared with those patients whose POD2 hFABP levels decreased from their post-CPB level (hazard ratio, 10.9; 95% CI, 5.0-23.7; P = 7.2 × 10(-10)). Mortality in the 120 patients (10%) with a later hFABP peak was 18.3%, compared with 4.7% in those who did not peak later. Alternatively, for cTnI or CK-MB, no difference in mortality was detected. CONCLUSION: Compared with traditional markers of myocardial injury after CABG surgery, hFABP peaks earlier and is a superior independent predictor of postoperative mortality and ventricular dysfunction.
BACKGROUND:Heart-type fatty acid binding protein (hFABP) functions as a myocardial fatty acid transporter and is released into the circulation early after myocardial injury. We hypothesized that hFABP is superior to conventional cardiac biomarkers for predicting early perioperative myocardial injury after coronary artery bypass graft (CABG) surgery. METHODS: A prospective cohort study of 1298 patients undergoing primary CABG with cardiopulmonary bypass (CPB) was performed at 2 institutions. Four plasma myocardial injury biomarkers (hFABP; cardiac troponin I [cTnI]; creatine kinase, MB [CK-MB] fraction; and myoglobin) were measured at 7 perioperative time points. The association among perioperative cardiac biomarkers and ventricular dysfunction, hospital length of stay (HLOS), and up to 5-year postoperative mortality (median 3.3 years) was assessed using Cox proportional hazard models. We defined in-hospital ventricular dysfunction as a new requirement for 2 or more inotropes, or new placement of an intraaortic balloon pump, or ventricular assist device either during the intraoperative period after the patient separated from CPB or postoperatively in the intensive care unit. RESULTS: The positive and negative predictive values of mortality for hFABP are 13% (95% confidence interval [CI], 9%-19%) and 95% (95% CI, 94%-96%), respectively, which is higher than for cTnI and CK-MB. After adjusting for clinical predictors, both postoperative day (POD) 1 and peak hFABP levels were independent predictors of ventricular dysfunction (P < 0.0001), HLOS (P < 0.05), and 5-year mortality (P < 0.0001) after CABG surgery. Furthermore, POD1 and peak hFABP levels were significantly superior to other evaluated biomarkers for predicting mortality. In a repeated-measures analysis, hFABP outperformed all other models of fit for HLOS. Patients with POD2 hFABP levels higher than post-CPB hFABP levels had an increased mortality compared with those patients whose POD2 hFABP levels decreased from their post-CPB level (hazard ratio, 10.9; 95% CI, 5.0-23.7; P = 7.2 × 10(-10)). Mortality in the 120 patients (10%) with a later hFABP peak was 18.3%, compared with 4.7% in those who did not peak later. Alternatively, for cTnI or CK-MB, no difference in mortality was detected. CONCLUSION: Compared with traditional markers of myocardial injury after CABG surgery, hFABP peaks earlier and is a superior independent predictor of postoperative mortality and ventricular dysfunction.
Authors: J H Veerkamp; R J Paulussen; R A Peeters; R G Maatman; H T van Moerkerk; T H van Kuppevelt Journal: Mol Cell Biochem Date: 1990 Oct 15-Nov 8 Impact factor: 3.396
Authors: J F Glatz; G J van der Vusse; M L Simoons; J A Kragten; M P van Dieijen-Visser; W T Hermens Journal: Clin Chim Acta Date: 1998-04-06 Impact factor: 3.786
Authors: K Suzuki; Y Sawa; K Kadoba; T Takahashi; H Ichikawa; K Kagisaki; T Ohata; H Matsuda Journal: Ann Thorac Surg Date: 1998-01 Impact factor: 4.330
Authors: Louis A Saddic; Tzuu-Wang Chang; Martin I Sigurdsson; Mahyar Heydarpour; Benjamin A Raby; Stanton K Shernan; Sary F Aranki; Simon C Body; Jochen D Muehlschlegel Journal: Physiol Genomics Date: 2015-07-14 Impact factor: 3.107
Authors: Ulrich H Frey; Jochen D Muehlschlegel; Jürgen Peters; Simon Body; Christoph Ochterbeck; Amanda A Fox; Stanton K Shernan; Charles D Collard; Peter Lichtner Journal: Anesthesiology Date: 2014-05 Impact factor: 7.892
Authors: Florian Rader; Akshat C Pujara; Gregory Pattakos; Jeevanantham Rajeswaran; Liang Li; Laurie Castel; Mina K Chung; A Marc Gillinov; Otto Costantini; David R Van Wagoner; Eugene H Blackstone Journal: Heart Rhythm Date: 2012-10-05 Impact factor: 6.343
Authors: Harsh Goel; Joshua Melot; Matthew D Krinock; Ashish Kumar; Sunil K Nadar; Gregory Y H Lip Journal: Ann Med Date: 2020-08-04 Impact factor: 4.709
Authors: Jennifer A Schaub; Amit X Garg; Steven G Coca; Jeffrey M Testani; Michael G Shlipak; John Eikelboom; Peter Kavsak; Eric McArthur; Colleen Shortt; Richard Whitlock; Chirag R Parikh Journal: Kidney Int Date: 2015-04-01 Impact factor: 10.612
Authors: Volkhard Göber; Andreas Hohl; Brigitta Gahl; Florian Dick; Verena Eigenmann; Thierry P Carrel; Hendrik T Tevaearai Journal: PLoS One Date: 2013-09-06 Impact factor: 3.240